ArriVent Targets PACC Mutation Market With EGFR TKI Firmonertinib In Lung Cancer
Drug Shows CNS Activity In Early Trial
Newly public company ArriVent BioPharma presented Phase Ib results at WCLC for its kinase inhibitor, which could be the first drug available specifically for hard-to-treat PACC mutations.
